Evidence map›Paper›PMID 41961189›Full record

ArticleInternational journal of clinical oncology2026

Predicting pathological lymph node status in clinical stage I/II tongue cancer.

Yusuke Nojima, Natsumi Kijima, Daisuke Sano, Daisuke Nishikawa, Seiya Goto, Kodai Tsuchida, Satoshi Kano, Yosuke Ariizumi, Yohei Morishita, Takashi Mukaigawa and 9 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yusuke NojimaDepartment of Otorhinolaryngology-Head and Neck Surgery, Yokohama City University, School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Natsumi KijimaDepartment of Otorhinolaryngology-Head and Neck Surgery, Yokohama City University, School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Daisuke SanoDepartment of Otorhinolaryngology-Head and Neck Surgery, Yokohama City University, School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. dsano@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0002-7686-4724
Daisuke NishikawaDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Aichi, Japan.
Seiya GotoDivision of Head and Neck Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Kodai TsuchidaDepartment of Otolaryngology-Head and Neck Surgery, Iwate Medical University, Yahaba, Morioka, Iwate, 028-3695, Japan.
Satoshi KanoDepartment of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15, W7, Kita-ku, Sapporo, 060-8638, Japan.
Yosuke AriizumiDepartment of Head and Neck Surgery, Institute of Science Tokyo, Tokyo, Japan.
Yohei MorishitaDepartment of Otorhinolaryngology, Head and Neck Surgery, Jikei University Hospital, Tokyo, Japan.
Takashi MukaigawaDivision of Head and Neck Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Kiyoto ShigaDepartment of Otolaryngology-Head and Neck Surgery, Iwate Medical University, Yahaba, Morioka, Iwate, 028-3695, Japan.
Takahiro AsakageDepartment of Head and Neck Surgery, Institute of Science Tokyo, Tokyo, Japan.
Kazuto MatsuuraDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Ryuichi HayashiDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Kouji YamamotoDepartment of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
Satoshi FujiiDepartment of Molecular Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
Nobuhiko OridateDepartment of Otorhinolaryngology-Head and Neck Surgery, Yokohama City University, School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Akihiro HommaDepartment of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15, W7, Kita-ku, Sapporo, 060-8638, Japan.
Nobuhiro HanaiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Aichi, Japan.

Funding

Japan Agency for Medical Research and Development JP24ck0106939
6 · The paper itself

Abstract

backgroundIt is difficult to accurately predict occult cervical lymph node metastasis, a major factor that significantly influences treatment outcomes in patients with clinical stage I/II tongue cancer. This study aimed to develop a predictive model for occult cervical lymph node metastasis in patients with stage I/II tongue cancer based on clinical and histopathological findings.

methodsThis multicenter cross-sectional study analyzed the archived pathological specimens and clinical records of patients diagnosed with stage I/II tongue cancer between January 2012 and March 2020 at seven institutions in Japan. All patients underwent transoral partial glossectomy with elective neck dissection, and the histological depth of invasion (DOI) was confirmed to be 3-10 mm. The clinicopathological features of the primary tumors were compared with those of occult cervical lymph node metastases. Predictive factors for occult cervical lymph node metastasis were identified using the least absolute shrinkage and selection operator (LASSO) regression model, and the model performance was evaluated using receiver operating characteristic (ROC) analysis.

resultsIn total, 106 patients were included in this study. The LASSO regression analysis identified three significant predictors of occult cervical lymph node metastasis: vascular invasion, poorly differentiated clusters (PDC), and DOI. The predictive model incorporating these factors achieved an area under the curve (AUC) of 0.713.

conclusionVascular invasion, PDC, and DOI are the key histopathological predictors of occult cervical lymph node metastasis in early-stage tongue cancer. External validation in larger cohorts is warranted to validate the utility of the predictive model developed in this study.

Indexed as

Lymphatic MetastasisLymph NodesTongue NeoplasmsAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedNeck DissectionNeoplasm StagingPrognosisDepth of invasionOccult cervical lymph node metastasisPoorly diff erentiated clustersPredictive modelStage I/II tongue cancer

Identifiers

PMID41961189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.